Pharmaceutical pricing conundrum: time to get rid of it?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.Signal transduction and targeted therapy · 2025
   Review
2. Pricing vaccines and drugs in Europe: worth differentiating?The European journal of health economics : HEPAC : health economics in prevention and care · 2021
   Article
3. Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?Journal of the Royal Society of Medicine · 2020
   Review
4. Comment on: 'NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence'.PharmacoEconomics · 2020
   Article
5. Comment on: 'The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study'.PharmacoEconomics · 2019
   Article
6. Conflict of interest disclosure: striking a balance?The European journal of health economics : HEPAC : health economics in prevention and care · 2019
   Article
7. Precision medicine and monoclonal antibodies: breach of promise?Croatian medical journal · 2019
   Article
8. Competition in health markets: is something rotten?Journal of the Royal Society of Medicine · 2019
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as